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Abstract. Hyperhomocysteinaemia, defined as an 
abnormally high plasma homocysteine concentration 
after an oral methionine load, is common in young 
( ^  50 years) patients with peripheral arterial occlusive 
disease. It is thought to predispose to atherosclerosis 
by injuring the vascular endothelium. Treatment with 
pyridoxine and/or folic acid may lower plasma homo­
cysteine levels, In mildly hyperhomocysteinaemic 
patients with peripheral arterial occlusive disease, we 
studied the effect of daily treatment with pyridoxine 
(250 mg) plus folic acid (5 mg) on homocysteine 
metabolism (i.e. plasma concentrations in the fasting 
state and after methionine loading, in 48 patients) and 
on endothelial function (in 18 patients), Endothelial 
function was estimated as the plasma concentrations 
of the endothelium-derived proteins, von Willebrand 
factor (vWF), thrombomodulin (TM), and tissue-type 
plasminogen activator (tPA). At baseline, fasting 
homocysteine levels were above normal in 24 of the 
48 patients (50%); post-load levels, by definition, were 
above normal in 100% of patients. After 12 weeks of 
treatment, fasting and post-load levels were normal in 
98 and 100% of patients, respectively. Endothelial 
function was assessed in 18 patients who completed 
1 year of treatment. At baseline, median vWF (235%) 
and TM (57'1 ngm L"1) levels were above normal. At 
follow-up, vWF levels had decreased to 170% 
(p =  0*01) and TM levels had decreased to 
49ngmL-1 (P =  0*04). tPA levels were normal at 
baseline and did not change. Endothelial dysfunction 
is present in young patients with peripheral arterial 
occlusive disease and hyperhomocysteinaemia. Pyri­
doxine plus folic acid treatment normalizes homocys­
teine metabolism in virtually all patients, and appears 
to ameliorate endothelial dysfunction.
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Introduction
Mild hyperhomocysteinaemia is an independent risk
factor for peripheral arterial occlusive disease [1.4].
Studies in animals and in vitro indicate that high 
plasma concentrations of homocysteine, derived 
from demethylation of dietary methionine, may pre­
dispose to atherosclerosis by injuring the vascular 
endothelium, which results in endothelial dysfunc­
tion [5—9]. Pyridoxine and/or folic acid supplementa­
tion have been shown to reduce plasma homocysteine 
concentrations in mildly hyperhomocystcinaemic 
patients with peripheral occlusive disease [10], but it 
is not known to what extent such treatment nor­
malizes homocysteine metabolism as estimated by 
plasma homocysteine concentrations in the fasting 
state and after an oral methionine load. It is also 
unknown whether endothelial dysfunction is present 
in these patients and, if so, whether treatment aimed 
at normalizing homocysteine metabolism improves 
endothelial function.
We assessed endothelial function in young patients 
with peripheral arterial occlusive disease and hyper­
homocysteinaemia as defined by an abnormal plasma 
concentration after methionine loading [1]. A gold 
standard for endothelial dysfunction is not available; 
we therefore measured plasma levels of three endo­
thelium-derived proteins involved in the regulation 
of haemostasis, i.e. von Willebrand factor (vWF), 
thrombomodulin (TM) and tissue-type plasminogen 
activator (tPA), because in vitro and in vivo data
suggest that endothelial injury is associated with 
increased plasma levels of these proteins [11-18]. In 
addition, we investigatèd the effects of treatment with 
pyridoxine plus folic acid on homocysteine meta­
bolism and endothelial function.
Patients and methods
Patients
Between November 1991 and April 1993, a total of
176
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Table 1. Clinical characteristics of patients with peripheral arterial
occlusive disease and hyperhomocysteinaemia
tion [1], Table 1 shows the clinical features of these 
patients. All had normal renal and hepatic function.
n (M/F) 48(17/31)
Age (years) 43-9 (1-1)
Blood pressure (mmHg) 138/87 (20/20)
Smokers 32 (67%)
Serum cholesterol (mmolL *) 6*3 (1*2)
Diabetes mellitus 2 (4%)
Scrum creatinine (/¿mo! L~!) 85 (21)
Data arc mean values (SD) unless otherwise indicated.
205 consecutive patients presenting with peripheral 
arterial occlusive disease and aged 50 years or younger 
were recruited from the Department of Vascular 
Surgery at the Free University Hospital, Amster­
dam. Symptomatic peripheral arterial occlusive 
disease was defined as intermittent claudication 
and/or ischaemic ulceration, rest pain and gangrene, 
and/or amputation for isehuemia, and was confirmed 
by Doppler and/or angiographic studies. After 
obtaining each patient's informed consent, clinical 
and laboratory data were collected.
Blood pressure was measured after 15 min of supine 
rest without altering antihypertensive regimens. Dia­
betes was defined according to WHO criteria, and 
known diabetes duration was recorded. Patients were 
classified as non-smokers (those who did not smoke 
cigarettes, cigars, or a pipe) or smokers (all others). 
Drug use was also recorded. After an overnight fast, 
blood was drawn for measurement of serum total 
cholesterol (measured enzymatically), creatinine 
(modified Jaffe reaction), glucose (glucose oxidase 
method), and endothelial function parameters (as 
specified below), and an oral methionine loading test 
was performed to detect hyperhomocysteinaemia. 
The clinical data were collected and laboratory 
assays performed by personnel ‘blinded1 to the pre­
sence of treatment with pyridoxine plus folic acid.
Methionine loading test
Plasma levels of homocysteine were determined in the 
fasting state and 6 h after an oral methionine load 
(0*1 g kg"'1). Plasma homocysteine levels were mea­
sured as total homocysteine by using HPLC with 
fluorescence detection [19], Normal fasting and post­
load values measured in our laboratory are <18 and 
<51 /¿mol L”"1, respectively, in men (// — 21), <15 and 
<49 fimol L respectively, in premenopausal women 
(n — 56), and < 19 and <69 ft mo IL 1, respectively, in 
postmenopausal women (n =  20). Deficiencies of 
vitamin Bj2, pyridoxine and folic acid were excluded 
by measuring serum levels. Normal values are 
>120pmolL 1 for vitamin Bj2, >17 nmol L" 1 for 
pyridoxine, and >3*4nmol L 1 for folic acid.
A total of 205 patients were tested in this way; 
48 (23%) of them had hyperhomocysteinaemia as 
defined by an abnormal post-load plasma concentra­
Main outcome measures
The 48 hyperhomocysteinaemia patients were all 
treated with pyridoxine (250 mg daily) plus folic acid 
(5 mg daily). The effect on fasting and post-load 
homocysteine levels was studied after 6 weeks and, 
in patients in whom the post-load plasma concentra­
tion at 6 weeks was not in the normal range, again 6 
weeks later. Parameters of endothelial function, and 
the effect of treatment on these parameters, were 
investigated in all patients who, in June 1993, had 
completed at least 1 year of treatment (n — 18). This 
period was chosen to allow a reasonable amount of 
time for the effect of treatment on endothelial function 
to become manifest.
Endothelial function. The plasma concentrations of 
von Willebrand factor antigen (vWF) [20], thrombo­
modulin (TM; Asserachrom Thrombomodulin, Diag- 
nostica Stago, Asmieres, France) [18], and tissue-type 
plasminogen activator antigen (tPA; Imulyse tPA, 
Biopool, Umea, Sweden) [21] were measured by 
enzyme-linked immunosorbent assays. The plasma 
vWF level is expressed as a percentage of normal 
pooled plasma, the antigen level of which is defined
as 100%) (normal range, 50.150% [13]). For TM and
tPA, normal ranges are 16-5~47,5ngm L ” 1 and 1 -84— 
9*80ngmL"1, respectively, as obtained in a control 
group (n — 21) matched for age with the 18 hypcrho- 
mocysteinacmic patients in whom TM and tPA were 
measured. All blood samples were taken between 
08.00 and 09.00 hours, after an overnight fast. We 
were careful to avoid acute increases in the concentra­
tions of these proteins associated with exercise, smok­
ing, prolonged venous occlusion, hypoglycaemia, and 
acute illness. The intra- and interassay version of the 
vWF, TM and tPA assays is less than 10%; the day- 
to-day variability of vWF within individuals is aboxit 
10%; that of tPA is about 15% (unpublished data).
Statistical analysis
Data are given as mean values (SD) or as median 
(range), unless otherwise indicated. Parametric and 
non-parametric tests were used as appropriate. Paired 
tests were used to compare baseline with post-treat­
ment data. We used univariate analysis to study the 
relationship between endothelial function and pos­
sible determinants thereof, including fasting and post­
load homocysteine levels as well as 'classic1 risk 
factors for atherosclerotic vascular disease (age, sex, 
smoking habits, systolic and diastolic blood pressure, 
and serum cholesterol; diabetes was not included in 
the analysis because there was only one diabetic 
among the 18 patients in the endothelial function 
study). The relationship of these ‘classic’ risk factors 
with endothelial function parameters was assessed
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Figure 1. Plasma homocysteine concentrations (fasting and after methionine loading) before and during treatment (6 weeks in 
45 patients and 12 weeks in three patients) with pyridoxine plus folic acid: O , men; A ,  premenopausal 
women; ▼, postmenopausal women.
both at baseline and at follow-up (i.e. at 1 year). In 
addition, we studied the relationship between homo­
cysteine levels (fasting and post-load) and endothelial 
function parameters at baseline and between homo­
cysteine levels after treatment (i.e. at 6 weeks) and 
endothelial function parameters at follow-up (i.e. at 1 
year). All testing was two-tailed, with a value of 0-05 
taken to be the level of significance.
Results
The patients reported no adverse effects of the pyri­
doxine plus folic acid treatment. No new vascular 
events occurred during follow-up, either in the 48 
patients followed for 6-12  weeks or in the subgroup 
of 18 patients followed for ^1  year. Mean (SD) 
fasting and post-load plasma homocysteine levels 
were 20*7 (14*7) and 73-8 (22*3) ¿¿molL“ 1 before 
treatment, and 9*6 (3*6) and 36*8 (9*l)//molL' 1 
after treatment (P < 0.001 for both comparisons; 
Fig. 1). By definition, post-load homocysteine con­
centrations before treatment were abnormal in all 
patients. In contrast, fasting concentrations were 
within the normal range in 24 of the 48 patients 
(50%). After 6 weeks of treatment, the fasting and
post-load homocysteine concentrations were within 
the normal range in 47 (98%) and 45 (94%) of 48 
patients, respectively. After 12 weeks, these figures 
were 47 (98%) and 48 (100%).
Table 2 shows the clinical characteristics of the 18 
patients who completed at least 1 year of treatment 
(and in whom endothelial function was assessed).
At baseline, vWF and TM levels were above 
normal, but tPA levels were in the normal range. At 
follow up, plasma vWF concentrations had decreased 
from median 235 to 170% (P =  0*01), and plasma TM 
concentrations had decreased from 57’1 to 
49*0 ngml" 1 (P =  0-04). Plasma tPA levels had not 
changed (6,9ngml~I at baseline vs. 6-5ngml~1 at 
follow-up [P =  0-91]; Table 2, Fig. 2).
With regard to the classic risk factors, significant 
relationships were observed at baseline (but not at 
follow-up) between age and tPA (r =  0-57, P — 0-01), 
serum cholesterol and vWF (r =  048, P =  0*04), and 
smoking habits and TM (smokers had lower TM 
levels than non-smokers (49 [29-72] vs. 70 [48- 
llSJngmL"1; P — 0*03).
The fasting homocysteine plasma levels at baseline 
and after 6 weeks of treatment were not related to 
endothelial function parameters at baseline and
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Figure 2. Endothelial function parameters before and after I year o f  treatment with pyridoxine plus folic acid: vW F, von 
Willebrand factor; TM, thrombomodulin; tPA, tissue-type plasminogen activator, §,1| =  values not to scale, o f  +  716 and 
-f-727 (§), and +454 (II), The black rectangles indicate the normal ranges,
follow-up, respectively, except for the homocysteine 
level at 6 weeks and the tPA level at follow-up 
(/• =  0-44, P =  0*06). In contrast, the post-load homo­
cysteine plasma levels at baseline and after 6 weeks of 
treatment showed trends towards significant relation­
ships with the endothelial function parameters at 
baseline and follow-up, respectively: vWF (baseline:
/• =  0*36, P ^ O ‘14; follow-up: r =  0*69, P =  0*001, 
Fig. 3), TM (baseline: r = 0*73, =  0-001; follow- 
up: r — 0*35, P  =  0*15), and tPA (baseline: r — 0*06, 
P =  0-8; follow-up: r =  0*38, ƒ>= 0-12).
Discussion
In keeping with earlier reports [1-4], our results
Tabic 2. Characteristics of the hyperhomocysteinaemic patients who
completed 1 year of treatment
Baseline Follow-up
indicate a high prevalence of mild hyperhomocystein­
aemia among young patients with peripheral arterial 
occlusive disease. Such patients show evidence of 
endothelial dysfunction as estimated by vWF and 
TM plasma concentrations. Endothelial dysfunction 
is thought to play an important role in atherogenesis. 
Treatment with pyridoxine plus folic acid normalizes 
homocysteine metabolism in virtually all patients, 
both in terms of the fasting homocysteine plasma 
level and the level after an oral methionine load.
Treatment with pyridoxine and folic acid is based 
on their involvement in homocysteine metabolism. 
Furthermore, both agents have been shown to lower 
the grossly elevated homocysteine plasma levels 
observed in classic homocystinuria, an inborn error 
of metabolism characterized by premature athero­
sclerosis and venous and arterial thromboembolism 
[4], Classic homocystinuria is usually caused by 
homozygous deficiency of cystathionine synthase, an 
enzyme involved in the conversion of homocysteine to
n (M/F) 18(6/12)
Age (years) 43*6(1*2) 44*6(1*2) 450
Follow-up duration 400
(months) 12*1 ( 12- 13)
Blood pressure N Û 350
(mniHg) 142/91 (18/26) 141/86(18/10) LL 300
Scrum cholesterol 5> 250
(mmolL l ) 6-3 (0*2) 6*0 (0*4) CLZ> 200 
J  f  A
Smoking (Y/N) 13/5 11/7
15
o
Diabetes mcllitus 1 (5*6%) 1 (5*6%) o
150
von Willebrand LL 100
factor (%) 235 170* 50
Thrombomodulin 0
( n g m L ']) 57*1 49 f
Tissue-type plasminogen
activator (n g n iL ■'•) 6-9 6*5
Q 10 20 30 40 SO GO 70
PoaMoad homocysteine level on treatment (f/mol L"')
so
Data arc mean values (SD) unless otherwise indicated. *P — 0*01; 
tP  =  0-04.
Figure 3. von Willebrand factor after I year o f  treatment with 
pyridoxine plus folic acid as a function o f  the post-methionine load 
plasma homocysteine concentration: r =  0 ‘69; P < 0*001.
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cystathionine. The active form of pyridoxine, pyri- 
doxal phosphate, is a cofactor in this reaction. Its 
homocysteine-lowering effect is thought to be due to 
stimulation of cystathionine synthase activity. In 
contrast, folic acid reduces the plasma homocysteine 
concentration by enhancing its remethyiation to 
methionine [4]. Therefore, the effects of these treat­
ment modalities can theoretically be expected to be 
additive.
Our patients were selected for having mild hyper­
homocysteinaemia, which may be due to heterozy­
gous cystathionine synthase deficiency [1] or to other 
metabolic defects [4,22]. Reliable and convenient 
methods to measure such deficiencies directly are 
not available at present. Instead, methionine load­
ing, which stresses the pathways involved in homo­
cysteine metabolism, can be used as a diagnostic test 
to uncover abnormalities of homocysteine handling. 
It is not clear which estimate of homocysteine meta­
bolism, fasting [3,23] or post-load [1,2] level should be 
chosen to guide treatment, because it is not known 
which is the better predictor of atherosclerotic disease. 
We therefore measured both, and observed no major 
differences in the metabolic efficacy of pyridoxine plus 
folic acid treatment, whether expressed as fasting or as 
post-load homocysteine concentrations.
Importantly, we found such treatment to be asso­
ciated with improvement, although not normaliza­
tion, of endothelial function, suggesting that 
hyperhomocysteinaemia-associated endothelial dys­
function might be reversible. Homocysteine, a highly 
reactive sulphur-containing amino acid, is thought to 
damage endothelial cells by several mechanisms, e.g. 
generation of hydrogen peroxide [7] and depletion of 
nitric oxide-mediated detoxification of homocysteine 
[9], In addition, as hyperhomocysteinaemia is often 
due to genetic defects in the enzymes that regulate 
homocysteine metabolism [1,2,4,22], and because 
these defects are also present in endothelial cells [8], 
the endothelium of these individuals may be particu­
larly vulnerable to homocysteine toxicity [6]. 
Endothelial dysfunction is a central feature of current 
models of atherogenesis [24]. Increased vWF and TM 
plasma concentrations probably reflect ongoing 
endothelial injury [11-16], Furthermore, high 
plasma vWF levels have been shown to predict a 
poor cardiovascular prognosis in survivors of myo­
cardial infarction [12] and in patients with non­
insulin-dependent diabetes mellitus [13]. The nature 
of the link between atherosclerosis and vWF and TM 
is not known with certainty. High vWF and TM are 
probably markers of the presence of endothelial injury 
and the process of atherogenesis. In addition, high 
plasma vWF levels may have functional significance 
because vWF enhances platelet adhesion and coagu­
lation, the latter by stabilizing factor VIII. TM, a 
membrane-bound protein, contributes to the inhibition 
of thrombin generation, thereby establishing an 
important local control of the coagulation cascade. 
Elevated TM plasma levels may reflect decreased
binding to the cell membrane [15], thus allowing 
enhanced thrombin activity or, alternatively, they 
may result from a homocysteine-induced increase in 
synthesis and turnover [25]. The precise mechanism 
by which hyperhomocysteinaemia increases vWF and 
TM plasma concentration is unknown. In vitro studies 
have suggested that homocysteine might decrease 
vWF secretion [26] and TM expression [27], findings 
that indicate major differences between the in vitro 
and in vivo situation.
The normal plasma level of tPA, an important 
regulator of fibrinolysis, suggests that endothelial 
function was not altered in this respect. However, 
interpretation is limited by the fact that we studied 
a relatively small group of patients. In addition, we 
did not measure tPA’s inhibitor, PAI-1, which 
together with tPA is thought to determine fibrinolytic 
capacity.
Other limitations of our study should also be 
considered. First, the treatment was neither rando­
mized nor controlled. It appears unlikely, however, 
that the substantial effect of treatment on homocys­
teine levels was a change finding, as such levels are 
known to be quite stable over time, whereas other 
conditions known to affect homocysteine metabolism 
were excluded [4]. In addition, although a placebo- 
controlled trial would obviously be the most prefer­
able study design, our experience with symptomatic 
hyperhomocysteinaemic patients suggests that many 
such patients would not consent to such a trial in view 
of the perceived safety and efficacy of vitamin therapy 
[4]. Second, we cannot be certain that the changes in 
endothelial function parameters were induced by the 
pyridoxine plus folic acid treatment, although this 
interpretation is supported by the strong correlation 
between post-treatment homocysteine and vWF levels 
(Fig. 3). However, the observed correlations between 
homocysteine levels and endothelial function para­
meters, although theoretically plausible, should be 
considered preliminary until they are confirmed in a 
larger group. As other cardiovascular risk factors did 
not change significantly during follow-up, changes in 
factors such as smoking habits are an unlikely explan­
ation for the observed decreases in vWF and TM. 
Furthermore, vWF levels are relatively stable over 
periods of up to 3 years in (diabetic) patients remain­
ing free of cardiovascular disease [13], suggesting that 
regression to the mean is also an unlikely explanation 
of the changes in vWF. Third, notwithstanding the 
promising effects of pyridoxine plus folic acid supple­
mentation on endothelial function parameters, the 
clinical efficiacy of the proposed treatment needs to 
be investigated in terms of prevention of new vascular 
events.
In conclusion, endothelial dysfunction is present 
in young patients with peripheral arterial occlusive 
disease and mild hyperhomocysteinaemia. Pyridoxine 
plus folic acid treatment normalizes homocysteine 
metabolism in the majority of patients, and appears 
to ameliorate endothelial dysfunction.
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In young patients with coronary artery or cerebro­
vascular disease, the effect of pyridoxine plus folic 
acid on homocysteine metabolism was similar to that
reported here [28].
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